The Acute-Phase Response in Relation to Radiographic Progression in Early Rheumatoid Arthritis: A Prospective Study During the First Three Years of the Disease

Leeuwen, M.A. van; Rijswijk, M.H. van; Heijde, D.M.F.M. van der; Meerman, Gjt; Riel, P.L.C.M. van; Houtman, P. M.; Putte, L. B. A. Van De; Limburg, P. C.

doi:10.1093/rheumatology/32.suppl_3.9

Cited by 156 publications

(95 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At baseline, patients were started on a regimen of either a single daily dose of tenidap (120 mg), hydroxychloroquine (400 mg/day) given as 2 equal doses plus piroxicam (20 Evaluation of efficacy. Clinical parameters.…”

Section: Methodsmentioning

confidence: 99%

“…In each case, transaminase levels returned to normal the treatment was stopped. Other abnormal findings leading to discontinuation of treatment included decreases in hemoglobin levels (1 tenidap patient, 2 hydroxychloroquine-plus-piroxicam patient), decreased white blood cell (WBC) counts (1 hydroxychloroquine-plus-piroxicam patient, 2 piroxicam alone patients), decreased proteinuria levels (1 tenidap pa- (20) 10 ( tient), and increased creatinine levels (1 hydroxychloroquine-plus-piroxicam patient). Proteinuria of >500 mg/24 hours was detected in 8 of the tenidap-treated patients and in 1 patient from each of the other 2 treatment groups (Table 6).…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Tenidap in rheumatoid arthritis a 24‐week double‐blind comparison with hydroxychloroquine‐plus‐piroxicam, and piroxicam alone

Blackburn¹,

Prupas²,

Silverfield

et al. 1995

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To compare the clinical efficacy, effect on serum C-reactive protein (CRP), serum amyloid A (SAA), and plasma interleukin-6 (IL-6) levels, and safety of tenidap with a combination of hydroxychloroquineplus-piroxicam, and piroxicam alone, in the treatment of rheumatoid arthritis (RA) patients.Methods. A double-blind, randomized, multicenter study in which patients with active RA were treated with tenidap 120 mg/day, hydroxychloroquine 400 mglday and piroxicam 20 mglday, or piroxicam alone 20 mglday, for 24 weeks.Results. At weeks 12 and 24, tenidap produced greater improvements than piroxicam based on 5 primary efficacy parameters; this improvement showed statistical significance in 4 of the 5 measures at week 12, and in 3 of the 5 measures at week 24. Clinical improvements in the hydroxychloroquine-plus-piroxicamtreated patients were similar to those seen in patients treated with tenidap. Compared with piroxicam, tenidap was associated with significantly greater reductions in serum CRP concentrations at 4, 12, and 24 weeks, and significantly greater reductions in SAA concentrations at weeks 12 and 24. The decrease in SAA concentrations was also significantly greater at weeks 4 and 24 in the tenidap-treated group than in the hydroxychloroquine-plus-piroxicam-treated group. Significant reductions in plasma IL-6 levels were observed at weeks 4, 12, and 24 within the tenidap group, and at week 24 within the hydroxychloroquine-plus-piroxicam-treated group. The overall occurrence of side effects, including gastrointestinal side effects, was similar in all 3 treatment groups. A small proportion of tenidap-treated

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

Tenidap in rheumatoid arthritis a 24‐week double‐blind comparison with hydroxychloroquine‐plus‐piroxicam, and piroxicam alone

Blackburn¹,

Prupas²,

Silverfield

et al. 1995

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…The effectiveness of treatment is monitored primarily by assessing the clinical inflammation parameters, and further by quantifying joint destruction on radiographs. A number of investigators have found disease activity parameters (often, acute-phase reactant levels) over time to be highly correlated with radiologic progression (4,5). In recent clinical trials, however, an uncoupling of inflammatory disease activity and radiologic progression has been suggested (6)(7)(8).…”

Section: Causes Radiologic Damage This Relationship Might Only Existmentioning

confidence: 99%

The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis

Welsing¹,

Landewé²,

Riel³

et al. 2004

Arthritis & Rheumatism

243

135

View full text Add to dashboard Cite

Objective. Radiologic progression in rheumatoid arthritis (RA) is considered the consequence of persistent inflammatory activity. To determine whether a change in disease activity is related to a change in radiologic progression in individual patients, we investigated the longitudinal relationship between inflammatory disease activity and subsequent radiologic progression.Methods. The databases of the University Medical Center Nijmegen (UMCN) cohort and the Maastricht Combination Therapy in RA (COBRA) followup study cohort were analyzed. The UMCN cohort included 185 patients with early RA who were followed up for up to 9 years. Patients were assessed every 3 months for disease activity and every 3 years for radiologic damage. The COBRA cohort included 152 patients with early RA who were followed up for up to 6 years. Patients were assessed at least every year for disease activity and every 12 months for radiologic damage. Disease activity was assessed with the Disease Activity Score (DAS) (original DAS in the UMCN cohort, DAS28 in the COBRA cohort). Conclusion. Radiologic progression is not linear in individual patients. Fluctuations in disease activity are directly related to changes in radiologic progression, which supports the hypothesis that disease activity

show abstract

“…CRP is a more direct measure of inflammation than ESR, and it is more sensitive to short-term changes (Kushner 1991). CRP production is associated with radiological progression in RA (Van Leeuwen 1993), and is considered at least as valid as ESR to measure RA disease activity (Mallya 1982, Wolfe 1997. Another advantage of determination of CRP is that waiting time for the laboratory result is shorter and that in case of multicenter studies a central laboratory can be used.…”

mentioning

confidence: 99%

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

et al. 2015

View full text Add to dashboard Cite

A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active psoriatic arthritis List of tables List of figures Glossary of termsAssessment A procedure used to generate data required by the study Control drug A study drug used as a comparator to reduce assessment bias, preserve blinding of investigational drug, assess internal study validity, and/or evaluate comparative effects of the investigational drug Enrollment Point/time of patient entry into the study; the point at which informed consent must be obtained (i.e. prior to starting any of the procedures described in the protocol)Inadequate response to TNFα Active disease despite stable treatment with anti-TNFa for at least 3 months at a stable dose or for at least one dose in the case of lack of tolerance Investigational drugThe study drug whose properties are being tested in the study; this definition is consistent with US CFR 21 Section 312.3 and is synonymous with "investigational new drug."Medication number A unique identifier on the label of each study drug package in studies that dispense study drug using an IVR systemPatient number A number assigned to each patient who enrolls in the study. When combined with the center number, a unique identifier is created for each patient in the study. PeriodA minor subdivision of the study timeline; divides phases into smaller functional segments such as screening, baseline, titration, washout, etc.Phase A major subdivision of the study timeline; begins and ends with major study milestones such as enrollment, randomization, completion of treatment, etc.Premature patient withdrawal Point/time when the patient exits from the study prior to the planned completion of all study drug administration and assessments; at this time all study drug administration is discontinued and no further assessments are plannedRandomization number A unique identifier assigned to each randomized patient, corresponding to a specific treatment arm assignment Stop study participation Point/time at which the patient came in for a final evaluation visit or when study drug was discontinued whichever is later Study drug Any drug administered to the patient as part of the required study procedures; includes investigational drug and any control drugs Study drug discontinuation Point/time when patient permanently stops taking study drug for any reason; may or may not also be the point/time of premature patient withdrawal Variable Information used in the data analysis; derived directly or indirectly from data collected using specified assessments at specified timepointsThis document (090095a88362b521 in docbase CREDI_BS) has been digitally signed with external signatures using Entrust PKI. Protocol synopsisTitle of study: A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and...

show abstract

The Acute-Phase Response in Relation to Radiographic Progression in Early Rheumatoid Arthritis: A Prospective Study During the First Three Years of the Disease

Cited by 156 publications

References 0 publications

Tenidap in rheumatoid arthritis a 24‐week double‐blind comparison with hydroxychloroquine‐plus‐piroxicam, and piroxicam alone

Tenidap in rheumatoid arthritis a 24‐week double‐blind comparison with hydroxychloroquine‐plus‐piroxicam, and piroxicam alone

The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Contact Info

Product

Resources

About